The largest database of trusted experimental protocols

Amd3100

Manufactured by Sanofi
Sourced in United States

AMD3100 is a small molecule that functions as a CXCR4 antagonist. It is used as a laboratory research tool to study the CXCR4 chemokine receptor and its role in various biological processes.

Automatically generated - may contain errors

3 protocols using amd3100

1

Inhibiting Malaria Sporozoite Infection

Check if the same lab product or an alternative is used in the 5 most similar protocols
For in vitro experiments, AMD3100 (1 µM; Sigma-Aldrich), anti-HGF (20 µg/ml; R&D Systems), PF184 (500 nM; Tocris), or FR182024 (10 µM; Merck Millipore) was added to cell culture media 4 h before infection. Each inhibitor and medium were changed at 0, 4, and 24 h after infection.
For in vivo experiments, AMD3100 (10 mg/kg) was intraperitoneally injected into mice at 24 and 12 h before infection. After intravenous infection of sporozoites, mice were injected with AMD3100 at 0, 12, and 24 h after infection. According to the manufacturer’s protocol for AMD3100 (also known as Plerixafor; Genzyme Plerixafor Injection Investigator's Brochure, 2009, version 13, May 27, 2009), a half-life of AMD3100 was previously shown to be ∼5–6 h. Also, the manufacturer reported that the effect of AMD3100 in vivo continues four half-life times (∼20–24 h). In addition, our preliminary experiments to test how often normal mice can be treated with AMD3100 suggested that mice treated with AMD3100 (10 mg/kg) every 6 h become unhealthy. Therefore, we decided to administer AMD3100 treatment in mice every 12 h; treatments were performed at 24 h and 12 h before infection and at 0 h, 12 h, and 24 h after infection.
+ Open protocol
+ Expand
2

Mobilization and Transplantation of Hematopoietic Stem Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Two‐ or 19‐month‐old C57BL/6NIA female mice were obtained through the NIA on a monthly basis and randomly assigned to their respective groups. HSCs were mobilized by administration of G‐CSF (Neupogen®, Filgrastim, Amgen) by intra‐peritoneal injections (125 µg/kg) every 12 hr for four consecutive days prior to transplantation. AMD3100 (Mozobil, Genzyme, Cambridge, MA) was administered (5 mg/kg) via subcutaneous injection 14 hr after the last dose of G‐CSF and 1 hr prior to HSC transplantation. Lineage‐negative donor cells (5.0 × 106) from eight‐week old GFP mice were transplanted into each G‐CSF/AMD3100‐treated recipient mouse via tail vein injection. For initial transplants, this procedure was repeated once every two weeks for a number of cycles corresponding to individual group numbers (i.e., group 1 received one transplant, group 2 received two transplant cycles, and so on, with group 7 receiving seven transplant cycles). For longevity studies, all recipients received a total eight transplants. For peripheral blood and bone marrow analyses, recipients received only one transplant. HSC transplant efficacy was assessed by determination of percentage of GFP‐positive versus. total WBCs in peripheral blood by flow cytometry (BD FACSCalibur System, BD Bioscience) at 1 and 4 months after the last transplantation cycle.
+ Open protocol
+ Expand
3

Mobilizing Stem Cells for Transplantation

Check if the same lab product or an alternative is used in the 5 most similar protocols
8-week old, female C57BL/6J mice were divided into seven groups (n = 3 per group). Mice from each group received G-CSF (Neupogen, Filgrastim, Amgen, Thousand Oaks, CA, USA) intra-peritoneal injections (125 μg/kg) every 12 hr for 4 consecutive days to mobilize resident HSCs prior to transplantation. AMD3100 (Mozobil, Genzyme, Cambridge, MA, USA) was administered (5 mg/kg) through subcutaneous injection 14 hr after the last dose of G-CSF and 1 hr prior to HSC transplantation. 8-week old GFP+ lineage-negative donor cells (2.0 × 106) were transplanted into each G-CSF/AMD3100-treated mouse via tail vein injection. This procedure was repeated once every 2 weeks for a number of cycles corresponding to individual group numbers (i.e., group 1 received one transplant, group 2 received two transplant cycles, and so on, with group 7 receiving seven transplant cycles). HSC transplant efficacy was assessed by determination of percentage of GFP-positive cells in peripheral blood by flow cytometry at 1 and 4 months after the last transplantation cycle. Data represent mean ± SD from three animals per different cycle of HSCT group (n = 3).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!